Interferon-α-2b/ribavirin-induced vestibulocochlear toxicity with dysautonomia in a chronic hepatitis C patient

European Journal of Gastroenterology and Hepatology

Volumn 20, Issue 11, 2008, Pages 1110-1114

  Johnson, Kristin ^a   Sargent, Lisa A ^a   Galizio, Christopher ^a   Ubogu, Eroboghene E ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Autonomic neuropathy; Hearing loss; Hepatitis C virus; Interferon ; Ribavirin; Tinnitus; Vertigo; Vestibulocochlear toxicity

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ANAMNESIS; ARTICLE; AUDIOMETRY; CASE REPORT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DRUG WITHDRAWAL; DYSAUTONOMIA; HEARING LOSS; HEPATITIS C; HUMAN; INNER EAR DISEASE; LABORATORY TEST; MALE; ORTHOSTATIC HYPOTENSION; PHYSICAL EXAMINATION; POSTURAL INTOLERANCE; PRIORITY JOURNAL; SIDE EFFECT; TINNITUS; VERTIGO; VESTIBULAR DISORDER; VESTIBULOCOCHLEAR TOXICITY;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEARING LOSS, SUDDEN; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RIBAVIRIN; TINNITUS; VERTIGO;

EID: 55349137392     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3282f8e583     Document Type: Article

References (19)

1. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436:967-972.
2. McHutchison JG, Gordon SC, Schiff ER, Shiftman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485-1492.
3. Arase Y, Ikeda K, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, et al. Adequate timing of ribavirin reduction in patients with hemotysis during combination therapy of interferon and ribavirin for chronic hepatitis C. J Gastroenterol 2004; 39:1090-1094.
4. Jarvis SM, Thorn JA, Glue P. Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters. Br J Pharmacol 1998; 123:1587-1592.
5. Kanda Y, Shigeno K, Matsuo H, Yano M, Yamada N, Kumagami H. Interferon-induced sudden hearing loss. Audiology 1995; 34:98-102.
6. Formann E, Stauber R, Denk DM, Jessner W, Zollner G, Munda-Steindl P, et al. Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin. Am J Gastroenterol 2004; 99:873-877.
7. Tunca A, Erbayrak M, Aytac S, Turkay C. Axonal neuropathy and hearing loss associated with alpha interferon treatment in chronic hepatitis B: a case report. Turk J Gastroenterol 2004; 15:97-99.
8. Irioka T, Yamada M, Yamawaki M, Saito Y, Mizusawa H, Yamada M, et al. Acute autonomic and sensory neuropathy after interferon alpha-2b therapy for chronic hepatitis C. J Neurol Neurosurg Psychiatry 2001; 70:408-410.
9. Boonyapisit K, Katirji B. Severe exacerbation of hepatitis C-associated vasculitic neuropathy following treatment with Interferon alpha: a case report and literature review. Muscle Nerve 2002; 25:909-913.
10. La Civita L, Zignego AL, Lombardini F, Monti M, Longombardo G, Pasero G, et al. Exacerbation of peripheral neuropathy during alpha-interferon therapy in a patient with mixed cryoglobulinemia and hepatitis B virus infection. J Rheumatol 1996; 23:1641-1643.
11. Batisse D, Karmochkine M, Jacquot C, Kazatchkine MD, Weiss L. Sustained exacerbation of cryogtobulinaemia-related vasculitis following treatment of hepatitis C with peginterferon alfa. Eur J Gastroenterol Hepatol 2004; 16:701-703.
12. Beuthien W, Mellinghoff HU, Kempis J. Vasculitic complications of interferon-alpha treatment for chronic hepatitis C virus infection: case report and review of the literature. Clin Rheumatol 2005; 24:507-515.
13. Briani C, Chemello L, Zara G, Ermani M, Bemardinello E, Ruggero S, et al. Peripheral neurotoxicity of pegytated Interferon alpha: a prospective study in patients with HCV. Neurology 2006; 67:781-785.
14. Lonsbury-Martin BL, Martin GK, McCoy MJ, Whrtehead ML New approaches to the evaluation of the auditory system and a current analysis of otoacoustic emissions. Otolaryngol Head Neck Surg 1995; 112: 50-63.
15. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus nbavinn for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352:1426-1432.
16. Van Vlierbergh H, Delanghe JR, De Vos M, Leroux-Roel G. Factors influencing ribavirin-induced hemotysis. J Hepatol 2001; 34:911-916.
17. Murofushi T, Takeuchi N, Ozeki H, Mizuno M. Acute vestibular dysfunction associated with interferon-alpha therapy. Eur Arch Otorhinolaryngol 1998; 255:77-78.
18. Goldstein DS, Pechnik S, Holmes C, Eldadah B, Sharabi Y. Association between supine hypertension and orthostatic hypotension in autonomic failure. Hypertension 2003; 42:136-142.
19. Biaggioni I, Robertson RM. Hypertension in orthostatic hypotension and autonomie dysfunction. Cardiol Clin 2002; 20:291-301.